Speak Easily
Greenlighter
- Joined
- Jan 17, 2024
- Messages
- 8
MAPS said:Looking ahead, the incoming Trump Administration presents both opportunities and questions for drug policy reform and psychedelic-assisted care. While President-elect Trump’s alliances may raise the visibility of psychedelics in public health discussions, we are hopeful that regulatory safeguards for patient and public health will remain intact. We support pathways that ensure ethical, safe access to psychedelic care while reinforcing critical regulatory frameworks that protect patients and the broader community.
MAPS remains optimistic about the future of federal support for psychedelic research through agencies like the Veterans Administration and the National Institutes of Health. We urge the incoming administration to engage with diverse stakeholders—from federal and state agencies to local community advocates—to shape policies that genuinely serve the public interest and uphold rigorous standards for safety and ethics.
Our commitment to fostering understanding, reducing stigma, ending the failed drug war, and advocating for equitable, safe access to psychedelic therapies remains steadfast. We look forward to collaborating with advocates everywhere to responsibly harness the transformative potential of psychedelics for the well-being of people and communities.
MAPS.org
